Grade downgraded from A+ to B+ (20 June 2026): The stock has rallied past the published $350 entry and TP1 ($380) is now only ~$8 away at spot $371.72 — R/R to TP1 is a dismal 0.21 and only 0.84 to TP2. Fundamentals remain excellent (4/4 beats, clean balance sheet), but the entry is gone. This is a hold-if-you-own, not a new buy at current levels. A fresh A+ would require a pullback to the rising EMA20 (~$351) with recalibrated targets.
Evercore is the cleanest pure-play on the reawakening M&A and advisory cycle. The franchise has now posted four consecutive, escalating earnings beats — culminating in a record Q1'26 adjusted EPS of $7.53 (vs $5.43 consensus) as adjusted advisory fees jumped 123% year over year Investing.com· Q1'26. At ~20x adjusted earnings on inflecting numbers, with a balance sheet that returns capital rather than dilutes it, this is a high-quality cyclical breakout setup — not a value trap.
Evercore is the largest independent investment-banking advisory firm in the world by revenue and now ranks as the #3 global advisory franchise by trailing-four-quarter advisory fees (~$4.0B), behind only Goldman Sachs (~$5.4B) and JPMorgan (~$4.1B) — having overtaken Morgan Stanley. Unlike the bulge brackets, Evercore takes no balance-sheet risk and runs no large trading book — it sells advice: M&A, restructuring, capital advisory, and shareholder engagement, plus a smaller Investment Management arm.
Two segments drive the model. Investment Banking & Equities — the engine — is where advisory fees, underwriting, and the Evercore ISI equities platform live. Investment Management contributes wealth and institutional asset management. Crucially, roughly 45% of net revenue is now non-M&A (restructuring, capital advisory, equities, underwriting), which diversifies the franchise across the cycle. Evercore reported a record $3.88B in FY25 net revenue, and the TTM figure has already climbed to ~$4.55B as the deal cycle reaccelerates StockAnalysis· TTM. A record class of newly hired Senior Managing Directors (SMDs) is the firm's forward pipeline: rainmakers take 12–24 months to ramp, so 2026 hiring seeds 2027 fees.
Evercore is an advisory investment bank, so the right lens is net revenue, the compensation ratio, advisory fees, operating margin and capital return — not gross margin or EBITDA. The key tell here is operating leverage: revenue is growing faster than comp, so margins are expanding.
| Metric | Value | Signal |
|---|---|---|
| Net Revenue (TTM) | $4.55B | Record · +18% vs FY25 |
| Net Revenue (FY25) | $3.88B | Record year |
| Adj. Advisory Fees (Q1'26) | ~$1.2B | +123% YoY |
| Adj. Compensation Ratio | 64% | -170 bps YoY |
| Adj. Operating Margin (Q1'26) | 25.3% | +870 bps YoY |
| Net Income (TTM) | $747M | Inflecting |
| Adj. EPS Diluted (TTM) | $18.56 | vs $14.56 FY25 (adj.) |
| P/E (TTM) | 20.0x | Reasonable on growth |
| Fwd P/E | 16.2x | Cycle-justified |
| Capital Returned (Q1'26) | $673.3M | Record · net buyback |
| Analyst Target (mean) | $374.60 | Buy consensus |
The valuation deserves a clear-eyed look. P/E ~20x is above Evercore's mid-cycle average for a reason — earnings are inflecting hard off a deal-cycle trough. On forward numbers the multiple is ~16x, and if the advisory upcycle persists, FY26 consensus EPS reinforces the mid-teens forward valuation. This is not a nosebleed multiple (no MPWR-style ~60x here); it is a quality cyclical paying ~20x at the start of an upswing, which keeps the valuation axis intact for the grade.
| Last Price | $371.72 |
| RSI (14) | 60.6 |
| EMA 20 | $350.80 |
| EMA 50 | $340.66 |
| EMA 200 | $317.45 |
| ATR (14) | $12.99 |
| Extension vs EMA20 | +6.0% |
Textbook bullish structure. The EMA stack is perfectly ordered — EMA20 ($350.80) > EMA50 ($340.66) > EMA200 ($317.45) — with price riding above all three. RSI at 60.6 sits in the healthy momentum band, well short of overbought, leaving room before any mean-reversion. Price is ~6.0% extended above the EMA20 — getting stretched but not extreme. ATR of $12.99 (~3.5%) frames clean risk: a pullback into the $350–$355 EMA20 zone is the high-probability entry, with the EMA50 around $341 acting as the trend floor. The stock sits ~4.5% below its 52-week high of $388.71 — narrower headroom for a measured-move push toward prior highs Yahoo Finance· live.
For a recommendation to clear our bar, the cap table has to be clean — no active ATM, no toxic financing, no dilutive capital raise, no reverse split. Evercore passes. A pull of the SEC EDGAR filing history (CIK 1360901) shows only routine forms — 8-K earnings releases, 10-Q/10-K, proxy DEF 14A, and insider Form 4s. There is a standing automatic shelf (S-3ASR) — boilerplate for any WKSI of this size — but it is not being tapped for cash equity offerings: no at-the-market program, no PIPE, no convertibles and no warrants. The only equity-plan filing is a routine S-8 (employee comp). The one share-issuance to flag is M&A consideration, not a capital raise: in October 2025 Evercore closed its acquisition of UK advisory firm Robey Warshaw, paying ~£71.25M (~$95M) via 275K Class A shares at closing, with a second ~£74.8M tranche due at the one-year anniversary (~October 2026) in stock or cash Evercore IR· Oct 2025. That M&A stock is <1% of the share count and the firm bought back far more than it issued — so Evercore remains a net repurchaser, not a dilutive issuer. However, the SBC pipeline deserves honest disclosure: as of December 2025 there were 4.8M unvested RSUs ($932M grant-date value) plus ~0.7M Class K-P performance units — a combined ~5.5M shares representing ~14% potential dilution if fully vested without offset. Management has offset this for five consecutive years via net-settlement repurchases (buybacks exceeding RSU grants every year), but the RSU overhang is structural and investors should monitor it. Note: the Robey Warshaw second tranche (~GBP 74.8M, due ~October 2026) may add further stock issuance if settled in shares rather than cash.
A high-quality franchise with a pristine balance sheet — but the highest-beta name in this cohort (1.49). The dominant risk is not company-specific; it is the cyclicality of the deal market itself. Advisory fees are the first line item to retreat if the M&A cycle stalls or the tape turns risk-off.
The company-specific risks here are genuinely low — no toxic dilution (though the RSU overhang is material at ~14%), no leverage stress, improving margins, a Buy consensus. What keeps the gauge at a moderate 5/10 is pure cyclicality: with a 1.49 beta, EVR is the cohort's highest-octane name, and its core revenue line is the most macro-sensitive. In a continuing risk-on, deal-friendly tape this is exactly the franchise you want; in a sharp risk-off, it draws down faster than its peers. Trade it as a high-conviction cyclical, not a defensive compounder.
⚠ At spot $371.72, this entry is no longer actionable. The original thesis (14 June): buy the highest-quality pure-play on the M&A reawakening into a controlled pullback to the $350 EMA20 zone. From a $350.00 limit entry, the $332.00 stop risks $18.00 while TP1 at $380.00 offers $30.00 — 1.67R to the first target, and 3.06R to $405.00. At current levels ($371.72), R/R collapses to 0.21R / 0.84R — well below the 1.5R minimum for a new position. Wait for a pullback to the rising EMA20 (~$351) before re-engaging, or treat this as a hold-if-you-own with a trailed stop.
This analysis is provided for informational and educational purposes only. It does not constitute financial advice, investment recommendation, or solicitation to buy or sell any security.
Past performance is not indicative of future results. All investments involve risk, including the possible loss of principal. Always conduct your own research and consult a licensed financial advisor before making investment decisions.
Data sourced from DailyTickers Gateway, Yahoo Finance, StockAnalysis, MarketBeat, and SEC EDGAR. Accuracy is not guaranteed.